ClinConnect ClinConnect Logo
Search / Trial NCT04673032

Radiofrequency (RF) Ablation Prospective Outcomes Study

Launched by BOSTON SCIENTIFIC CORPORATION · Dec 12, 2020

Trial Information

Current as of June 17, 2025

Completed

Keywords

Radiofrequency (Rf)

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Key Inclusion Criteria:
  • Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain per local Directions for Use (DFU)
  • Signed a valid, IRB/EC/REB-approved informed consent form
  • Key Exclusion Criteria:
  • Meets any contraindications per locally applicable Directions for Use (DFU)
  • Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments

About Boston Scientific Corporation

Boston Scientific Corporation is a global leader in medical device innovation, dedicated to providing solutions that enhance patient care and improve clinical outcomes. With a strong focus on advancing the treatment of various medical conditions, Boston Scientific develops and manufactures a diverse range of products across multiple specialties, including cardiology, urology, and endoscopy. The company is committed to rigorous clinical research and development, ensuring that its devices meet the highest standards of safety and efficacy. Through collaboration with healthcare professionals and ongoing investment in technology and education, Boston Scientific strives to deliver breakthrough therapies that address unmet medical needs and empower patients worldwide.

Locations

Atlanta, Georgia, United States

Toledo, Ohio, United States

Geldrop, , Netherlands

Quincy, Illinois, United States

Tucson, Arizona, United States

London, , United Kingdom

Düsseldorf, , Germany

Sewickley, Pennsylvania, United States

Edina, Minnesota, United States

Huntersville, North Carolina, United States

Loveland, Ohio, United States

Mesa, Arizona, United States

Westport, Connecticut, United States

Cincinnati, Ohio, United States

Gainesville, Florida, United States

Brugge, , Belgium

Olbia, , Italy

Antwerp, , Belgium

Patients applied

0 patients applied

Trial Officials

Natalie Bloom Lyons, M.S.

Study Director

Boston Scientific Corporation

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials